Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Gene Therapy Product QA Documentation May Become Key IND Element - FDA

Executive Summary

Manufacturing quality assurance documentation could become a key component of gene therapy IND submissions, FDA Cellular & Gene Therapies Division Director Philip Noguchi, MD, suggested April 5.

You may also be interested in...



Adenovirus Vector Standards Should Be Loosened For Healthier Patients

FDA should loosen the standard for levels of replication-competent adenovirus in gene therapy products for all but the most severely immunocompromised patients, the Biological Response Modifiers Advisory Committee suggested July 13.

Adenovirus Vector Standards Should Be Loosened For Healthier Patients

FDA should loosen the standard for levels of replication-competent adenovirus in gene therapy products for all but the most severely immunocompromised patients, the Biological Response Modifiers Advisory Committee suggested July 13.

Gene Therapy Trial Monitors Must Not Report To Sponsor-Investigators - Cmte

Clinical monitors for gene therapy trials must be independent from sponsor-investigators, FDA's Biological Response Modifiers Advisory Committee concluded April 5.

UsernamePublicRestriction

Register

OM008605

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel